[news 2005-2006]

Cytochroma acquires Proventiv Therapeutics to commercialize new vitamin D products

For immediate release

Thursday, June 29, 2006

MARKHAM, ON – Cytochroma Inc., a spinoff company of Queen’s University’s PARTEQ Innovations, is pleased to announce that it has acquired Proventiv Therapeutics LLC of Madison, WI. The acquisition expands Cytochroma’s broad vitamin D product portfolio and uniquely positions the company to exploit current and future opportunities in chronic kidney disease (CKD), psoriasis, cancer, vitamin D deficiency and related disorders.The acquisition also establishes a Cytochroma United States base of operations in Madison, Wisconsin.

The combined company now has multiple lead candidates in clinical development for psoriasis and entering clinical development for vitamin D deficiency and secondary hyperparathyroidism in patients with moderate to severe CKD.

“This acquisition is very good news for Cytochroma,” says John Molloy, President and CEO of PARTEQ Innovations. “It significantly enhances their product potential, and their capacity to move to the next level.”

The acquisition brings an experienced executive team with a proven track record of success in vitamin D product commercialization in North America.

Cytochroma was founded in 1996 by Queen’s scientists Martin Petkovich and Glenville Jones to develop and identify drug candidates aimed at modulating the effects of cytochrome P450s, the key enzymes involved in the metabolism of major biological signalling molecules. Cytochroma’s focus on vitamin D Signal Amplifer products has applications in secondary hyperparathyroidism relating to chronic kidney disease, oncology, and multiple sclerosis.

Contact:
John Molloy
President & CEO
PARTEQ Innovations
P: 613. 533. 2342
F: 613. 533. 6853
jmolloy@parteqinnovations.com